Companies /Healthcare

Lexicon Pharmaceuticals Inc

NASDAQ: LXRX Biotechnology
$1.75
▼ $0.04 (−2.23%) today
Markets closed · 7:11pm ET

LXRX at a Glance

Valuation
Market cap
$797.0M
Profitability
Revenue (TTM)
$38.5M
Profit margin
-161.8%
EPS (TTM)
$-0.15
Price
52-week range
$1 – $3
Street target
$4.52

Headquartered in The Woodlands, TX Fiscal year ends December NASDAQ: LXRX lexpharma.com

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company developing novel medicines for serious cardiometabolic diseases, building on its legacy in genetic target discovery.

Its lead asset is sotagliflozin, an oral dual SGLT1/SGLT2 inhibitor studied in about 20,000 patients:
- Marketed in the U.S. for heart failure as INPEFA.
- In the pivotal Phase 3 SONATA-HCM trial for obstructive and non-obstructive hypertrophic cardiomyopathy.
- Planned for an NDA resubmission as ZYNQUISTA for glycemic control in adults with type 1 diabetes.

Viatris holds the sotagliflozin license for all indications outside the U.S. and Europe.

Lexicon has licensed LX9851, a first-in-class oral non-incretin ACSL5 inhibitor for obesity, to Novo. That deal carries up to $1 billion in potential milestones (of which $75 million has been earned) plus tiered royalties.

It is also developing pilavapadin (LX9211), a once-daily oral AAK1 inhibitor that is Phase 3-ready for diabetic peripheral neuropathic pain and being explored in obesity.

Revenue currently comes mainly from licensing and milestone payments, plus modest INPEFA product sales. Updated

LXRX Coverage

11:30am ET
Health and Healthcare

What Lexicon Pharma Could Mean for the Future of Diabetes

Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on the Marketing Authorization of Zynquista (sotagliflozin).

Chris Lange

Frequently Asked Questions

What does Lexicon Pharmaceuticals do?

Lexicon Pharmaceuticals is a biopharmaceutical company developing novel medicines for serious cardiometabolic diseases, building on its legacy in genetic target discovery.

What is the LXRX stock price target?

The Wall Street consensus 12-month price target for LXRX is $4.52.